Vascular Solutions Comments on VNUS Patent Litigation Related to Vari-Lase Products.
Howard Root, CEO of Vascular Solutions, commented: "Although we have not yet been served in this litigation, we have analyzed the patents issued and assigned to VNUS Medical concerning the use of tumescent anesthesia in their radiofrequency procedure for the treatment of varicose veins. We believe that Vascular Solutions' activities and our Vari-Lase products do not infringe these patents, and we intend to vigorously defend this action."
About Vascular Solutions
Vascular Solutions, Inc. is a medical device company that focuses on developing unique solutions for unmet clinical opportunities within Interventional radiology and Interventional cardiology. New products introduced since the second half of 2003 include the Vari-Lase(R) endovenous laser product line for the treatment of varicose veins, the D-Stat Dry(TM) hemostatic bandage for the rapid control of topical bleeding, the Pronto(TM) extraction catheter for the mechanical extraction of soft thrombus and the Langston(TM) dual lumen catheter for the measurement of aortic stenosis. The Company's other major products include the Duett(TM) sealing device to rapidly seal the puncture site following catheterization procedures, the D-Stat(R) Flowable hemostat for the local management of active bleeding, and the Acolysis(R) intravascular therapeutic ultrasound product which is sold in international markets for the treatment of peripheral occlusive arterial disease.
The information in this press release contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements. Important factors that may cause such differences include those discussed in our Annual Report on Form 10-K for the year ended December 31, 2004 and other recent filings with the Securities and Exchange Commission. The risks and uncertainties include, without limitation, risks associated with the need for adoption of our new products, limited working capital, lack of profitability, exposure to intellectual property claims, dependence on key vendors, exposure to possible product liability claims, the development of new products by others, doing business in international markets, limited manufacturing experience, the availability of third party reimbursement, and actions by the FDA.
For further information, connect to http://www.vascularsolutions.com/ .
CONTACT: Howard Root, CEO, or James Hennen, CFO, both of Vascular Solutions, Inc., +1-763-656-4300
Web site: http://www.vascularsolutions.com/
|Printer friendly Cite/link Email Feedback|
|Comment:||Vascular Solutions Comments on VNUS Patent Litigation Related to Vari-Lase Products.|
|Date:||Oct 10, 2005|
|Previous Article:||Caterpillar Expands Electric Power Manufacturing Operations in North America.|
|Next Article:||Aladdin Knowledge Systems Announces Date of Third Quarter 2005 Financial Results Release, Adjusted Revenue Guidance, Conference Call and Webcast.|